CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden

Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes

(2022) Nikolaos Zacharakis et al.   JOURNAL OF CLINICAL ONCOLOGY

Bystander CD4+ T cells infiltrate human tumors and are phenotypically distinct

(2022) Shamin Li et al.   OncoImmunology

Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer

(2022) Rom Leidner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers

(2022) Frank J. Lowery et al.   SCIENCE

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

(2022) Andrea Cercek et al.   NEW ENGLAND JOURNAL OF MEDICINE

Robust Antitumor Immunity in a Patient with Metastatic Colorectal Cancer Treated with Cytotoxic Regimens

(2021) Venkatesh Rajamanickam et al.   Cancer Immunology Research

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade

(2021) Romain Banchereau et al.   Journal for ImmunoTherapy of Cancer

Systematic analysis of CD39, CD103, CD137, and PD‐1 as biomarkers for naturally occurring tumor antigen‐specific TILs

(2021) Monika A. Eiva et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

The outcome of ex vivo TIL expansion is highly influenced by spatial heterogeneity of the tumor T-cell repertoire and differences in intrinsic in vitro growth capacity between T-cell clones

(2020) Isabel C Poschke et al.   CLINICAL CANCER RESEARCH

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

(2020) Myriam Chalabi et al.   NATURE MEDICINE

CD39 identifies the CD4+ tumor-specific T cell population in human cancer

(2020) Kim E Kortekaas et al.   Cancer Immunology Research

Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer

(2020) Sri Krishna et al.   SCIENCE

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells

(2020) Camille-Charlotte Balança et al.   JCI Insight

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma

(2019) Bradley D. Shields et al.   CANCER RESEARCH

Revisiting immune escape in colorectal cancer in the era of immunotherapy

(2019) Marieke Erica Ijsselsteijn et al.   BRITISH JOURNAL OF CANCER

TOX is a critical regulator of tumour-specific T cell differentiation

(2019) Andrew C. Scott et al.   NATURE

Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers

(2019) Maria R. Parkhurst et al.   Cancer Discovery

Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes

(2019) Alena Gros et al.   JOURNAL OF CLINICAL INVESTIGATION

A 40-Marker Panel for High Dimensional Characterization of Cancer Immune Microenvironments by Imaging Mass Cytometry

(2019) Marieke E. Ijsselsteijn et al.   Frontiers in Immunology

Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4

(2019) Jitske van den Bulk et al.   Genome Medicine

TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis

(2018) Daniele V. F. Tauriello et al.   NATURE

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

(2018) Daniela S. Thommen et al.   NATURE MEDICINE

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

(2018) Thomas Duhen et al.   Nature Communications

Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-naive ovarian cancer

(2018) Sara Bobisse et al.   Nature Communications

Cancer immunotherapy: broadening the scope of targetable tumours

(2018) Jitske van den Bulk et al.   Open Biology

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates

(2018) Yannick Simoni et al.   NATURE

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

(2018) Derin B. Keskin et al.   NATURE

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

(2017) Michael J Overman et al.   LANCET ONCOLOGY

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

CD103 and Intratumoral Immune Response in Breast Cancer

(2016) Z.-Q. Wang et al.   CLINICAL CANCER RESEARCH

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

(2016) Eric Tran et al.   NEW ENGLAND JOURNAL OF MEDICINE

VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research

(2016) Zhongwu Lai et al.   NUCLEIC ACIDS RESEARCH

CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy

(2016) Fenne L. Komdeur et al.   Oncotarget

Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells

(2015) Sanja Stevanović et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunogenicity of somatic mutations in human gastrointestinal cancers

(2015) E. Tran et al.   SCIENCE

CD39 Expression Identifies Terminally Exhausted CD8+ T Cells

(2015) Prakash K. Gupta et al.   PLoS Pathogens

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

(2014) Alena Gros et al.   JOURNAL OF CLINICAL INVESTIGATION

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

(2014) E. Tran et al.   SCIENCE

Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer

(2013) J. R. Webb et al.   CLINICAL CANCER RESEARCH

CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor

(2013) Q. Ye et al.   CLINICAL CANCER RESEARCH

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

(2013) Kristian Cibulskis et al.   NATURE BIOTECHNOLOGY

Strelka: accurate somatic small-variant calling from sequenced tumor–normal sample pairs

(2012) Christopher T. Saunders et al.   BIOINFORMATICS

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration

(2012) H. Thorvaldsdottir et al.   BRIEFINGS IN BIOINFORMATICS

VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing

(2012) D. C. Koboldt et al.   GENOME RESEARCH

Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha

(2011) Els M. E. Verdegaal et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

(2011) S. A. Rosenberg et al.   CLINICAL CANCER RESEARCH

Integrative genomics viewer

(2011) James T Robinson et al.   NATURE BIOTECHNOLOGY

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

(2010) A. McKenna et al.   GENOME RESEARCH

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

(2008) Mark E. Dudley et al.   JOURNAL OF CLINICAL ONCOLOGY